Blog - Litchlab

EN

CN

{$ImageUrl,alt}

Blog

Home>Blog

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine Delivery

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine DeliveryLiposomes, as crucial carriers for vaccine delivery, possess unique structural and functional characteristics that enable them to meet the complex needs of various vaccines. Fr...

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma In May 2024, the U.S. Food and Drug Administration (FDA) announced the approval of irinotecan lipos...

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development Driven by the COVID-19 pandemic, mRNA vaccines and lipid nanoparticle (LNP) delivery systems have become key technologies i...

Litchlab Launches Advanced Hydrogel Drug Delivery CDMO Services to Meet the Global Demand for Next-Generation Therapeutics

Litchlab, a contract development and manufacturing organization (CDMO) specialized in drug delivery innovation, officially announces the launch of its Hydrogel Drug Delivery Technology Platform, offering integrated CDMO services for global pharmaceutical and b...

Litchlab Launches Comprehensive Non-GMP API Supply Platform to Accelerate Global IND Submissions

As global drug development accelerates and early-stage pipelines proliferate, Active Pharmaceutical Ingredient (API) services are undergoing a strategic shift—from traditional production models to research-enabling, regulatory-conscious solutions. Litchlab tod...

修改后.jpg

Extended Press Release — Litchlab’s Process Optimization Services in Clinical API CDMO

Litchlab, a Contract Development and Manufacturing Organization (CDMO) committed to intelligent drug delivery and synthesis technologies, today unveiled an enhanced platform for process optimization of clinical-stage Active Pharmaceutical Ingredients (APIs). T...

Litchlab Expands Clinical API CDMO Services to Support Global Drug Development with Sustainable, Scalable Solutions

Litchlab, a Contract Development and Manufacturing Organization (CDMO) specializing in advanced drug delivery technologies, today announces the strategic expansion of its clinical Active Pharmaceutical Ingredient (API) services. The enhanced offering includes ...

Litchlab Expands CDMO Services to Fluorescent Dyes & Molecular Probes: Enabling the Future of Optical Diagnostics and Theranostics

Litchlab, a Contract Development and Manufacturing Organization (CDMO) specialized in next-generation drug delivery and diagnostic platforms, has announced the official launch of its Fluorescent Dyes & Molecular Probes CDMO Service Line, providing end-to-e...

Litchlab Launches Comprehensive Carrier CDMO Platform to Power Next-Generation Drug Delivery

In response to the growing complexity of modern therapeutics—such as mRNA vaccines, gene editors, antibody-drug conjugates (ADCs), and extracellular vesicles (EVs)—Litchlab today officially launched its Integrated Drug Carrier CDMO Platform, offering a f...

上一页 1 2 3 4 5 下一页